Intelligence Feed event · Equity · 2026-09-18

    Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage

    Question

    Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage

    Direct answer

    Eli Lilly posted $27.7 billion in aggregate sales for its GLP-1 franchise, driven by Mounjaro and Zepbound, during the first half of 2026. The pharmaceutical company is progressing its metabolic pipeline diversification with oral therapy Foundayo securing widespread formulary coverage across major US pharmacy benefit managers. Complementary growth from newer therapies rose 121% during the second quarter, providing revenue support as the stock consolidates after a 7% one-month pullback.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-18
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage”, revision 1, evidence through 2026-09-18. https://marketontology.com/market-events/2026-09-18/eli-lilly-glp-1-revenue-reaches-27-7b-in-h1-2026-as-oral-obesity-drug-expands-co-945ab6

    EQUITY
    Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage
    Eli Lilly posted $27.7 billion in aggregate sales for its GLP-1 franchise, driven by Mounjaro and Zepbound, during the first half of 2026. The pharmaceutical company is progressing its metabolic pipeline diversification with oral therapy Foundayo securing widespread formulary coverage across major US pharmacy benefit managers. Complementary growth from newer therapies rose 121% during the second quarter, providing revenue support as the stock consolidates after a 7% one-month pullback.
    LLYNVO
    Impact
    70
    SEP 18
    SIG
    85%
    LLYNVO
    Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage
    Eli Lilly posted $27.7 billion in aggregate sales for its GLP-1 franchise, driven by Mounjaro and Zepbound, during the first half of 2026. The pharmaceutical company is progressing its metabolic pipeline diversification with oral therapy Foundayo securing widespread formulary coverage across major US pharmacy benefit managers. Complementary growth from newer therapies rose 121% during the second quarter, providing revenue support as the stock consolidates after a 7% one-month pullback.
    → Broadened PBM formulary access for oral obesity candidate Foundayo accelerates commercial patient onboarding, underpinning multi-year cash flow visibility across LLY's metabolic pipeline.
    Impact
    Eli Lilly posted $27.7 billion in aggregate sales for its GLP-1 franchise, driven by Mounjaro and Zepbound, during the first half of 2026. The pharmaceutical company is progressing its metabolic pipeline diversification with oral therapy Foundayo securing widespread formulary coverage across major US pharmacy benefit managers. Complementary growth from newer therapies rose 121% during the second quarter, providing revenue support as the stock consolidates after a 7% one-month pullback.
    Affected
    LLYNVO
    Transmission
    Broadened PBM formulary access for oral obesity candidate Foundayo accelerates commercial patient onboarding, underpinning multi-year cash flow visibility across LLY's metabolic pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYcommercial volume scaling through expanded PBM reimbursement coverageUp1-3mGLP-1 sales reached $27.7B in H1 2026 with oral pill Foundayo gaining major PBM coverage.
    NVOmarket share competition in oral metabolic obesity formulationsMixed1-3mFoundayo expansion pressures peer pricing in commercial pharmacy benefit tiers.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    NVOMixed43.24 2026-09-18-7.96%-10.27%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month